The DOI matches its Crossref record; 85 of the 87 references it cites were found in a registry or an index, and 1 are not checked yet.
Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review
Open accessAbstract
Adjuvant hormonal therapy significantly improves long-term survival of breast cancer patients with hormone receptor-positive disease. Despite the proven clinical efficacy of tamoxifen and aromatase inhibitors, many breast cancer survivors either fail to take the correct dosage at the prescribed frequency (adherence) or discontinue therapy (persistence). This systematic review aims to: (1) determine the prevalence of adherence and persistence to adjuvant hormonal therapy among breast cancer survivors in clinical practice, and (2) identify correlates of adherence and persistence. We searched Medline, PubMed, PsycINFO, and CINAHL for studies that measured rates and/or correlates of adherence and/or persistence to adjuvant hormonal therapy. Studies were reviewed in a multi-step process: (1) the lead author screened titles and abstracts of all potentially eligible studies; (2) each coauthor reviewed a random 5 % sample of abstracts; and (3) two sets of coauthors each reviewed half of all “maybe” abstracts. Any disagreements were discussed until consensus was reached. Twenty-nine studies met inclusion criteria. Prevalence of adherence ranged from 41 to 72 % and discontinuation (i.e., nonpersistence) ranged from 31 to 73 %, measured at the end of 5 years of treatment. Extremes of age (older or younger), increasing out-of-pocket costs, follow-up care with a general practitioner (vs. oncologist), higher CYP2D6 activity, switching from one form of therapy to another, and treatment side effects were negatively associated with adherence and/or persistence. Taking more medications at baseline, referral to an oncologist, and earlier year at diagnosis were positively associated with adherence and/or persistence. Adherence and persistence to adjuvant hormonal therapy among breast cancer survivors is suboptimal. Many of the correlates of adherence and persistence studied to date are not modifiable. Our review reveals a critical need for further research on modifiable factors associated with adherence to adjuvant hormonal therapy, and the development of behavioral interventions to improve adherence in this population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“A meta-analysis reported 31%–73% of breast cancer survivors are adherent to AET,10”
From Refining and optimising a behavioural intervention to support endocrine therapy adherence (ROSETA) in UK women with breast cancer: Protocol for a pilot fractional factorial trial (2023) · cites this paper as [10]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, non-adherence is common with up to three-quarters of women prescribed adjuvant endocrine therapy (HT) taking < 80% of prescribed therapy and similar proportions discontinuing prematurely [4].”
From Acceptance and Commitment Therapy to support medication decision-making and quality of life in women with breast cancer: protocol for a pilot randomised controlled trial (2022) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A number of barriers to medication use have been reported in this setting, including medication side-effects, psychological distress and a lack of social support [4, 15].”
From Acceptance and Commitment Therapy to support medication decision-making and quality of life in women with breast cancer: protocol for a pilot randomised controlled trial (2022) · cites this paper as [4]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Non -adherence to adjuvant endocrine therapy (AET) in women with breast cancer is common and associated with medication side -effects and distress.”
The cited source says what the claim attributes to it.
In the citing paper
“Adherence to adjuvant endocrine therapy is affected by medication side-effects and associated distress.”
The cited source says what the claim attributes to it.
In the citing paper
“However, non-adherence is common with up to three-quarters of women prescribed adjuvant endocrine therapy (HT) taking < 80% of prescribed therapy and similar proportions discontinuing prematurely [4].”
The cited source says what the claim attributes to it.
In the citing paper
“Non-adherence to AET is a major problem among women with breast cancer [4]”
In the citing paper
“Despite these benefits, between 31-73% of survivors discontinue adjuvant hormonal therapy in clinical practice,6 thereby reducing treatment efficacy.7-10”
From Behavioral interventions to enhance adherence to hormone therapy in breast cancer survivors: a systematic literature review (2016) · cites this paper as [6]
In the citing paper
“However, few interventions have been developed to improve adjuvant hormonal therapy adherence.6”
From Behavioral interventions to enhance adherence to hormone therapy in breast cancer survivors: a systematic literature review (2016) · cites this paper as [6]
In the citing paper
“Patient variables (e.g., age), social support, patient-provider communication, and healthcare factors (e.g., cost) have been associated with breast cancer survivor adherence to systemic therapies.6, 16-18”
From Behavioral interventions to enhance adherence to hormone therapy in breast cancer survivors: a systematic literature review (2016) · cites this paper as [6]
In the citing paper
“However, adherence to hormonal therapy is suboptimal.”
From Behavioral interventions to enhance adherence to hormone therapy in breast cancer survivors: a systematic literature review (2016) · cites this paper as [6]
In the citing paper
“While hormonal treatment related side effects such as hot flashes and osteoporosis42 represent one of the main reasons for discontinuation,6 none of the retrieved interventions had an explicit focus on side effects.”
From Behavioral interventions to enhance adherence to hormone therapy in breast cancer survivors: a systematic literature review (2016) · cites this paper as [6]
In the citing paper
“Although studies have shown that adherence is problematic in both older and younger women similarly,6 the reasons for discontinuation or barriers to adherence may be different between the two groups.”
From Behavioral interventions to enhance adherence to hormone therapy in breast cancer survivors: a systematic literature review (2016) · cites this paper as [6]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.005 · Cited by 19,575
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.006 · Cited by 10,578
Tamoxifen for early breast cancer: an overview of the randomised trials
Abe, O., Bartholomeus, S., & Piccart, M. J. (1998) · The Lancet · doi:10.1016/s0140-6736(97)11423-4 · Cited by 4,180
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2011) · The Lancet · doi:10.1016/s0140-6736(11)60993-8 · Cited by 3,075
From Cancer Patient to Cancer Survivor: Lost in Transition
(2005) · PsycEXTRA Dataset · doi:10.1037/e720092007-001 · Cited by 2,364
Howell, A., Cuzick, J. M., Baum, M., Buzdar, A. U., Dowsett, M., Forbes, J., Hoctin-Boes, G., Houghton, J., Locker, G. Y., & Tobias, J. S. (2005) · The Lancet · doi:10.1016/s0140-6736(04)17666-6 · Cited by 2,284
Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., Castiglione, M., Tu, D., Shepherd, L. E., Pritchard, K. I., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032312 · Cited by 1,795
Coombes, R. C., Hall, E., Gibson, L. J., Paridaens, R., Jassem, J., Delozier, T., Jones, S. E., Alvarez, I., Bertelli, G., Ortmann, O., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040331 · Cited by 1,759
Research works printed but not linked: 1
- Salgado BA, Zivian MT (2006) Aromatase inhibitors: side effects reported by 622 women. Breast Cancer Res Treat 100:S1618
Cited by
Sorted by citations
Items 201–300 of 710
Drooger, J. C., Jager, A., Lam, M.-H., den Boer, M. D., Sleijfer, S., Mathijssen, R. H. J., & de Bruijn, P. (2015) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2015.06.018 · Cited by 24
Santa-Maria, C. A., Bardia, A., Blackford, A. L., Snyder, C. F., Connolly, R. M., Fetting, J. H., Hayes, D. F., Jeter, S. C., Miller, R. S., Nguyen, A., et al. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4811-1 · Cited by 24
Adherence and quality of life in women with breast cancer being treated with oral hormone therapy
Stahlschmidt, R., Ferracini, A. C., de Souza, C. M., de Medeiros, L. M., Juliato, C. R. T., & Mazzola, P. G. (2019) · Supportive Care in Cancer · doi:10.1007/s00520-019-04671-x · Cited by 27
Salgado, T. M., Davis, E. J., Farris, K. B., Fawaz, S., Batra, P., & Henry, N. L. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4177-9 · Cited by 25
Predicting nonadherence to adjuvant endocrine therapy in women with early stage breast cancer
Corter, A. L., Broom, R. J., Porter, D. J. T., Harvey, V. J., & Findlay, M. P. N. (2018) · Psycho-Oncology · doi:10.1002/pon.4771 · Cited by 24
Sheppard, V. B., Sutton, A. L., Hurtado‐de‐Mendoza, A., He, J., Dahman, B. A., Edmonds, M. C., Hackney, M. H., & Tadesse, M. G. (2021) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-20-0604 · Cited by 25
Lemij, A. A., de Glas, N. A., Derks, M. G. M., Bastiaannet, E., Merkus, J. W. S., Lans, T. E., van der Pol, C. C., van Dalen, T., Vulink, A. J. E., van Gerven, L., et al. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06583-7 · Cited by 23
Initiation of Adjuvant Endocrine Therapy in Black and White Women With Breast Cancer
Sheppard, V. B., de Mendoza, A. H., He, J., Jennings, Y., Edmonds, M. C., Oppong, B. A., & Tadesse, M. G. (2017) · Clinical Breast Cancer · doi:10.1016/j.clbc.2017.12.002 · Cited by 23
Taylor, L. J., Steiman, J. G., Anderson, B. M., Schumacher, J. R. M., Wilke, L. G., Greenberg, C. C., & Neuman, H. B. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05579-5 · Cited by 23
Liu, X., Lü, J., Wang, G., Chen, X., Xv, H., Huang, J., Xue, M.-X., & Tang, J. (2021) · Integrative Cancer Therapies · doi:10.1177/1534735420980811 · Cited by 23
Alessandro de, S. I. R. E., Lippi, L., Ammendolia, A., Cisari, C., Venetis, K., Sajjadi, E., Fusco, N., & Invernizzi, M. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11121369 · Cited by 25
Adjuvant endocrine therapy in premenopausal women with breast cancer.
Kadakia, K. C., & Henry, N. L. (2015) · PubMed · Cited by 22
Moon, Z., Moss-Morris, R. E., Hunter, M. S., & Hughes, L. D. (2020) · Supportive Care in Cancer · doi:10.1007/s00520-020-05850-x · Cited by 23
Hall, L., King, N. V., Graham, C. D., Green, S. M. C., Barber, A., Neal, R. D., Foy, R., Clark, J., Lloyd, K. E., & Smith, S. G. (2021) · Journal of Cancer Survivorship · doi:10.1007/s11764-021-01114-7 · Cited by 22
Ballinger, T. J., Thompson, W. R., & Guise, T. A. (2022) · Breast Cancer Research · doi:10.1186/s13058-022-01576-2 · Cited by 22
Tan, X., Camacho, F., Marshall, V. D., Donohoe, J., Anderson, R. T., & Balkrishnan, R. (2016) · Research in Social and Administrative Pharmacy · doi:10.1016/j.sapharm.2016.08.004 · Cited by 22
Applying the theory of planned behavior to examine adjuvant endocrine therapy adherence intentions
Hurtado‐de‐Mendoza, A., Carrera, P., Parrott, W. G., Gómez‐Trillos, S., Perera, R. A., & Sheppard, V. B. (2018) · Psycho-Oncology · doi:10.1002/pon.4931 · Cited by 25
Marsden, J., Marsh, M., Rigg, A. S., & on behalf of The British Menopause Society (2019) · Post Reproductive Health · doi:10.1177/2053369118824920 · Cited by 22
New Insights Into Nonadherence With Adjuvant Endocrine Therapy Among Young Women With Breast Cancer
Rosenberg, S. M., & Partridge, A. H. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv245 · Cited by 22
Hurtado‐de‐Mendoza, A., Cabling, M. L., & Sheppard, V. B. (2015) · Nursing Inquiry · doi:10.1111/nin.12101 · Cited by 21
Rapid Modulation of Aromatase Activity in the Vertebrate Brain
Charlier, T. D., Cornil, C. A., & Balthazart, J. (2013) · Journal of Experimental Neuroscience · doi:10.4137/jen.s11268 · Cited by 21
Reibold, C., Wakuma, T., Eber-Schulz, P., Getachew, S., Addissie, A., Unverzagt, S., Wienke, A., Hauptmann, S., Wickenhauser, C., Vetter, M., et al. (2021) · Breast Care · doi:10.1159/000512840 · Cited by 22
Association of sarcopenia with endocrine therapy toxicity in patients with early breast cancer
Aleixo, G. F. P., Valente, S. A., Wei, W., & Moore, H. C. F. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06741-x · Cited by 21
Desbiens, C., Filion, M., Brien, M.-C., Hogue, J., Laflamme, C., & Lemieux, J. (2017) · The Breast · doi:10.1016/j.breast.2017.06.001 · Cited by 21
Verbeek, J. G. E., Atema, V., Mewes, J. C., van Leeuwen, M., Oldenburg, H. S. A., van Beurden, M., Hunter, M. S., van Harten, W. H., Aaronson, N. K., & Retèl, V. P. (2019) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05410-w · Cited by 22
Yusufov, M., Nathan, M., Wiley, A., Russell, J. A., Partridge, A. H., & Joffe, H. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05920-y · Cited by 21
Chan, P.-W., Chiu, J., Huang, N., Chen, C., Yu, H., Liu, C., & Hsu, C.-H. (2020) · Phytomedicine · doi:10.1016/j.phymed.2020.153365 · Cited by 21
Smith, S. G., Green, S. M. C., Ellison, R., Foy, R., Graham, C. D., Mason, E., French, D. P., Hall, L. H., Wilkes, H., McNaught, E., et al. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-069971 · Cited by 20
Smale, E. M., Egberts, T. C. G., Heerdink, E. R., van den Bemt, B. J. F., & Bekker, C. L. (2021) · Research in Social and Administrative Pharmacy · doi:10.1016/j.sapharm.2021.12.004 · Cited by 20
Johnsson, A., Fugl-Meyer, K. S., Bordás, P., Åhman, J., & von Wachenfeldt, A. (2023) · Breast Cancer Basic and Clinical Research · doi:10.1177/11782234221145440 · Cited by 20
Estrogen therapy after breast cancer diagnosis and breast cancer mortality risk
Sund, M., Garmo, H., Andersson, A., Margolin, S., Ahlgren, J., & Valachis, A. (2023) · Breast Cancer Research and Treatment · doi:10.1007/s10549-023-06871-w · Cited by 20
Adjuvant therapy use among Appalachian breast cancer survivors
Tan, X., Marshall, V. D., Anderson, R. T., Donohoe, J., Camacho, F., & Balkrishnan, R. (2015) · Medicine · doi:10.1097/md.0000000000001071 · Cited by 20
“Winging It”: How Older Breast Cancer Survivors Persist With Aromatase Inhibitor Treatment
Brauer, E. R., Ganz, P. A., & Pieters, H. C. (2016) · Journal of Oncology Practice · doi:10.1200/jop.2016.011767 · Cited by 21
Extended Adjuvant Endocrine Therapy in Breast Cancer: Evidence and Update - A Review
Jinih, M., Relihan, N., Corrigan, M. A., O’Reilly, S., & Redmond, H. P. (2017) · The Breast Journal · doi:10.1111/tbj.12783 · Cited by 20
Karavites, L. C., Kane, A., Zaveri, S. R., Xu, Y., Helenowski, I., Hansen, N. M., Bethke, K. P., Rasmussen‐Torvik, L. J., & Khan, S. A. (2017) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-17-0029 · Cited by 20
Kuba, S., Maeda, S., Matsumoto, M., Yamanouchi, K., Yano, H., Morita, M., Sakimura, C., Hatachi, T., Tokai, Y., Takatsuki, M., et al. (2017) · Clinical Breast Cancer · doi:10.1016/j.clbc.2017.12.003 · Cited by 21
Xu, H., Zhang, X., Wang, D., Xu, L., & Wang, A. (2019) · Journal of Advanced Nursing · doi:10.1111/jan.14253 · Cited by 22
Adjuvant hormonal therapy for early breast cancer: an epidemiologic study of medication adherence
Pourcelot, C., Orillard, É., Nallet, G., Dirand, C., Billion-Rey, F., Barbier, G., Chouk, S., Limat, S., Montcuquet, P., Henriques, J., et al. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4676-3 · Cited by 20
Cahir, C., Barron, T. I., Sharp, L., & Bennett, K. (2017) · Cancer Causes & Control · doi:10.1007/s10552-017-0851-9 · Cited by 20
Atema, V., van Leeuwen, M., Kieffer, J. M., Oldenburg, H. S. A., van Beurden, M., Hunter, M. S., & Aaronson, N. K. (2019) · Maturitas · doi:10.1016/j.maturitas.2019.09.007 · Cited by 19
Neuman, H. B., Weiss, J. M., Schrag, D., Ronk, K., Havlena, J. A., LoConte, N. K., Smith, M. A., & Greenberg, C. C. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-013-3170-8 · Cited by 19
Bluethmann, S. M., Alfano, C. M., Clapp, J. D., Luta, G., Small, B. J., Hurria, A., Cohen, H. J., Sugarman, S. M., Muss, H. B., Isaacs, C. J., et al. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4353-y · Cited by 19
Self-citationChatsiproios, D., Schmidts-Winkler, I. M., König, L., Masur, C., & Abels, C. (2019) · PLoS ONE · doi:10.1371/journal.pone.0210967 · Cited by 19
Sheppard, V. B., He, J., Sutton, A. L., Cromwell, L., Adunlin, G., Salgado, T. M., Tolsma, D., Trout, M., Robinson, B. E., Edmonds, M. C., et al. (2019) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2019.25.5.578 · Cited by 19
Sella, T., & Chodick, G. (2019) · Breast Care · doi:10.1159/000500318 · Cited by 20
Mao, D., Hachem, H., Chang, H., Dima, D., Dower, J., Wismer, M., Erban, J. K., Freund, K. M., & Parsons, S. K. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05892-z · Cited by 20
Gomaa, S., West, C., López, A. M., Zhan, T., Schnoll, M., Abu-Khalaf, M. M., Newberg, A. B., & Wen, K. (2022) · JMIR Formative Research · doi:10.2196/34995 · Cited by 21
L’adhésion thérapeutique aux traitements oraux : enjeux en oncologie - l’exemple du cancer du sein
Huiart, L., Bardou, V., & Giorgi, R. (2013) · Bulletin du Cancer · doi:10.1684/bdc.2013.1830 · Cited by 23
Testing a behavioral intervention to improve adherence to adjuvant endocrine therapy (AET)
Shelby, R. A., Dorfman, C. S., Bosworth, H. B., Keefe, F., Sutton, L., Owen, L., Corsino, L., Erkanli, A., Reed, S. D., Arthur, S. S., et al. (2019) · Contemporary Clinical Trials · doi:10.1016/j.cct.2018.11.010 · Cited by 18
Hormone receptor-positive early breast cancer in young women: A comprehensive review
Walbaum, B., García-Fructuoso, I., Martínez‐Sáez, O., Schettini, F., Sanchez, C. G., Francisco Acevedo, C., Chic, N., Carrillo, F. J. M. I., Adamo, B., Muñoz-Mateu, M., et al. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102804 · Cited by 18
Assessing Predictors of Tamoxifen Nonadherence in Patients with Early Breast Cancer
Montagna, E., Zagami, P., Masiero, M. A., Mazzocco, K., Pravettoni, G., & Munzone, E. (2021) · Patient Preference and Adherence · doi:10.2147/ppa.s285768 · Cited by 18
Alnaim, L. S. (2022) · European Journal of Breast Health · doi:10.4274/ejbh.galenos.2022.2022-5-8 · Cited by 18
Bandiera, C., Locatelli, I., Courlet, P., Cardoso, E., Zaman, K., Stravodimou, A., Dolcan, A., Sarivalasis, A., Zurcher, J.-P., Aedo-Lopez, V., et al. (2023) · Cancers · doi:10.3390/cancers15010316 · Cited by 18
An Update on Tamoxifen and the Chemo-Preventive Potential of Vitamin E in Breast Cancer Management
Khallouki, F., Hajji, L., Saber, S., Bouddine, T., Edderkaoui, M., Bourhia, M., Mir, N., Lim, A., Midaoui, A. E., Giesy, J. P., et al. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13050754 · Cited by 18
Todd, A., Waldron, C., Hackshaw‐McGeagh, L., Norris, R. P., Bolnykh, I., Stewart, S.-J., Slodkowska‐Barabasz, J., Moon, Z., Cahir, C., Thompson, S. E., et al. (2024) · Cancer Medicine · doi:10.1002/cam4.6937 · Cited by 19
Benedict, C., Thom, B., Teplinsky, E., Carleton, J., & Kelvin, J. F. (2016) · Clinical Breast Cancer · doi:10.1016/j.clbc.2016.12.002 · Cited by 18
Dean, L. T., George, M., Lee, K. T., & Ashing, K. T. (2020) · Cancer · doi:10.1002/cncr.32946 · Cited by 19
Smith, S. G., Ellison, R., Hall, L., Clark, J., Hartley, S., Mason, E., Metherell, J., Olivier, C., Napp, V., Naik, J., et al. (2022) · Pilot and Feasibility Studies · doi:10.1186/s40814-022-00985-6 · Cited by 17
“The training will outline the psychological challenges of living with breast cancer and HTs, general ACT principles and the practice of ACTION intervention-specific therapy methods.”
BackgroundInfluentialMartinez, J. A., Taljanovic, M. S., Witte, R. S., Zuniga, A. A. N., Wertheim, B. C., Kwoh, C. K., Goldstein, B. A., Roe, D. J., & Chalasani, P. (2021) · Journal of Ultrasonography · doi:10.15557/jou.2021.0001 · Cited by 17
Jacobs, F., D’Amico, S., Zazzetti, E., Gaudio, M., Benvenuti, C., Saltalamacchia, G., Gerosa, R., Gentile, D., Lasagna, A., Pedrazzoli, P., et al. (2024) · Digital Health · doi:10.1177/20552076241288821 · Cited by 22
Ochayon, L., Tunin, R., Yoselis, A., & Kadmon, I. (2014) · European Journal of Oncology Nursing · doi:10.1016/j.ejon.2014.11.003 · Cited by 17
Tervonen, H. E., Daniels, B. J., Tang, M., Preen, D. B., & Pearson, S. (2019) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4751 · Cited by 18
Mohamed, K. E. H., & Elamin, A. (2020) · Journal of Evaluation in Clinical Practice · doi:10.1111/jep.13373 · Cited by 19
Challenges in the Treatment of Older Breast Cancer Patients
Williams, G. R., Jones, E., & Muss, H. B. (2013) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2013.05.008 · Cited by 17
Bergkvist, K., Fossum, B., Johansson, U., Mattsson, J., & Larsen, J. (2017) · European Journal of Cancer Care · doi:10.1111/ecc.12672 · Cited by 17
Relationships between determinants of adjuvant endocrine therapy adherence in breast cancer
Lee, J. Y., & Min, Y. H. (2018) · BMC Women s Health · doi:10.1186/s12905-018-0522-3 · Cited by 18
Weight Loss Interventions and Breast Cancer Survival: The Time Is Now
Irwin, M. L. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.4583 · Cited by 17
Ito, K., Elkin, E. B., Blinder, V. S., Keating, N. L., & Choudhry, N. K. (2013) · Cancer · doi:10.1002/cncr.28084 · Cited by 16
Jacobs, J. M., Walsh, E. A., Rapoport, C. S., Antoni, M. H., Park, E. R., Post, K. E., Comander, A. H., Peppercorn, J. M., Safren, S. A., Temel, J. S., et al. (2020) · Journal of Clinical Psychology in Medical Settings · doi:10.1007/s10880-020-09750-4 · Cited by 18
Beko, Z. W., Mengistu, D., Dinegde, N. G., Asefa, T., & Wassie, M. (2021) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s311445 · Cited by 17
Ambre, P., Gupta, C. R., Naik, I., Menon, M., & Coutinho, E. C. (2022) · Current Drug Delivery · doi:10.2174/1567201819666220408095510 · Cited by 16
He, Y., Tan, E. H., Wong, A. L. A., Tan, C. C., Wong, P., Lee, S. C., & Tai, B. C. (2018) · BMC Cancer · doi:10.1186/s12885-018-4660-7 · Cited by 16
Physical Health Decline After Chemotherapy or Endocrine Therapy in Breast Cancer Survivors
Bodelón, C., Masters, M., Bloodworth, D. E., Briggs, P. J., Rees‐Punia, E., McCullough, L. E., Patel, A. V., & Teras, L. R. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.62365 · Cited by 15
Yang, S., Park, S. W., Bae, S. J., Ahn, S. G., Jeong, J., & Park, K. (2023) · Journal of Breast Cancer · doi:10.4048/jbc.2023.26.e22 · Cited by 16
Gomaa, S., López, A., Slamon, R., Smith, R. M., Telushi, E., Lapitan, E., Nightingale, G., Miller, S., & Wen, K. (2023) · Supportive Care in Cancer · doi:10.1007/s00520-023-08170-y · Cited by 15
Side-effects in women treated with adjuvant endocrine therapy for breast cancer
Rademaker, L. M., Gal, R., May, A. M., Batenburg, M. C. T., van der Leij, F., Bijlsma, R. M., Verkooijen, H. M., Doeksen, A., Ernst, M. F., Evers, D. J., et al. (2025) · The Breast · doi:10.1016/j.breast.2025.104416 · Cited by 18
Targeted Therapies in Breast Cancer: Implications for Advanced Oncology Practice
Bourdeanu, L., & Luu, T. H. (2014) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2014.5.4.2 · Cited by 15
Jhawar, S. R., Alpert, N., Taioli, E., Sayan, M., Bazan, J. G., Park, K. U., Stover, D. G., Cherian, M. A., White, J. R., Haffty, B. G., et al. (2020) · Cancer Medicine · doi:10.1002/cam4.3443 · Cited by 15
Buijs, S. M., Hoop, E. O., Braal, C. L., van Rosmalen, M. M., Drooger, J. C., van Rossum‐Schornagel, Q. C., Vastbinder, M. B., Koolen, S. L. W., Jager, A., & Mathijssen, R. H. J. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.100786 · Cited by 15
Nardin, S., Ruffilli, B., Landolfo, T. L., Isingrini, G., Taglialatela, I., Delbarba, A., D’Avanzo, F., Rossi, V., Celentano, E., Conte, B., et al. (2025) · Cancers · doi:10.3390/cancers17172726 · Cited by 17
Saraf, A., Tahir, I., Hu, B. Y., Dietrich, A.-S. W., Tonnesen, P. E., Sharp, G. C., Tillman, G., Roeland, E. J., Nipp, R. D., Comander, A. H., et al. (2023) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2023.07.018 · Cited by 14
Sasada, S., Kondo, N., Hashimoto, H., Takahashi, Y., Terata, K., Kida, K., Sagara, Y., Ueno, T., Anan, K., Suto, A., et al. (2023) · Breast Cancer Research and Treatment · doi:10.1007/s10549-023-07097-6 · Cited by 15
Smith, K. L., Tsai, H., Lim, D., Wang, C., Nunes, R., Wilkinson, M. J., Sheng, J. Y.-S., Couzi, R. J., Fetting, J. H., Riley, C. D., et al. (2023) · JCO Oncology Practice · doi:10.1200/op.23.00038 · Cited by 15
Physical activity and pain in people with cancer: a systematic review and meta-analysis
Peters, M., Butson, G., Mizrahi, D., Denehy, L., Lynch, B. M., & Swain, C. T. V. (2024) · Supportive Care in Cancer · doi:10.1007/s00520-024-08343-3 · Cited by 14
Patient experience of menopause care after breast cancer in the UK: a cross-sectional study
Glynne, S., Reisel, D., Kamal, A., & Newson, L. R. (2025) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000002504 · Cited by 14
Chen, T. W., Chen, H., Lin, C., Huang, C., Cheng, A., Lai, M., & Lu, Y. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3140-2 · Cited by 14
Gregory, B. J., Chen, S., Murphy, M. A., Atchley, D. H., & Kamdem, L. K. (2017) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12569 · Cited by 14
Green, E., Wodajo, A., Yang, Y.-J., Sleven, M., & Pieters, H. (2017) · Cancer Nursing · doi:10.1097/ncc.0000000000000522 · Cited by 8
Clement, Z., Kollias, J., Bingham, J., Whitfield, R. J., & Bochner, M. A. (2018) · Gland Surgery · doi:10.21037/gs.2018.08.03 · Cited by 14
Boyne, D. J., O'Sullivan, D. E., Heer, E. V., Hilsden, R. J., Sajobi, T. T., Cheung, W. Y., Brenner, D. R., & Friedenreich, C. M. (2020) · Cancer Medicine · doi:10.1002/cam4.2843 · Cited by 11
Dragvoll, I., Bofin, A. M., Søiland, H., Taraldsen, G., & Engstrøm, M. J. (2022) · BMC Cancer · doi:10.1186/s12885-022-10362-4 · Cited by 14
Optimal adjuvant therapy in older (≥70 years of age) women with low-risk early-stage breast cancer
Chadha, M., White, J. R., Swain, S. M., Rakovitch, E., Jagsi, R., Whelan, T. J., & Sparano, J. A. (2023) · npj Breast Cancer · doi:10.1038/s41523-023-00591-6 · Cited by 14
Komatsu, H., Yagasaki, K., & Yamaguchi, T. (2016) · BMC Nursing · doi:10.1186/s12912-016-0130-1 · Cited by 15
A prospective study of aromatase inhibitor therapy initiation and self-reported side effects
Gallicchio, L. M., Calhoun, C., & Helzlsouer, K. J. (2017) · Supportive Care in Cancer · doi:10.1007/s00520-017-3678-8 · Cited by 15
Treatment Decisions and Adherence to Adjuvant Endocrine Therapy in Breast Cancer
Wassermann, J., & Rosenberg, S. M. (2017) · Current Breast Cancer Reports · doi:10.1007/s12609-017-0248-5 · Cited by 14
Keskey, R. C., LaJoie, A. S., Sutton, B. S., Kim, I. K., Cheadle, W. G., McMasters, K. M., & Ajkay, N. (2017) · Annals of Surgical Oncology · doi:10.1245/s10434-017-6094-x · Cited by 14
Sutton, A. L., Salgado, T. M., He, J., Hurtado‐de‐Mendoza, A., & Sheppard, V. B. (2020) · Supportive Care in Cancer · doi:10.1007/s00520-019-05247-5 · Cited by 14
Hertz, D. L., Smith, K. L., Zong, Y., Gersch, C. L., Pesch, A. M., Lehman, J., Blackford, A. L., Henry, N. L., Kidwell, K., Rae, J. M., et al. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.662734 · Cited by 14
Spring, L. M., Scarpetti, L., Medford, A. J., Niemierko, A., Comander, A. H., Mulvey, T. M., Schnipper, L. E., Isakoff, S. J., Moy, B., Wander, S. A., et al. (2025) · npj Breast Cancer · doi:10.1038/s41523-024-00708-5 · Cited by 13
Labonté, M., Guillaumie, L., Dionne, A. R., Dorval, M., Nabi, H., Lemieux, J., Provencher, L., & Lauzier, S. (2020) · Research in Social and Administrative Pharmacy · doi:10.1016/j.sapharm.2020.02.004 · Cited by 13
Metadata
- Authors
- Murphy, C. C., Bartholomew, L. K., Carpentier, M. Y., Bluethmann, S. M., & Vernon, S. W.
- Affiliations
- The University of Texas Health Science Center at Houston (US)
- Corresponding author
- Murphy, Caitlin C.
- Venue
- Breast Cancer Research and Treatment
- Published
- 2012-06-12
- Volume
- 134
- Issue
- 2
- Pages
- 459-478
- ISSN
- 0167-6806 (ISSN-L)
- 1573-7217
- PMC
- PMC3607286
- OpenAlex
- W1987753117
- Semantic Scholar
- 92816b1cff05e88d3955bfa52d7d9c9f3eafb040
- Cited by
- 708
- References
- 85
- Citations by year
- 2026: 32 · 2025: 63 · 2024: 59 · 2023: 67 · 2022: 71 · 2021: 59 · 2020: 60 · 2019: 54 · 2018: 41 · 2017: 64 · 2016: 33 · 2015: 38 · 2014: 32 · 2013: 34 · 2012: 1
- FWCI
- 4.41
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Breast Cancer Research and Treatment (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Cancer Institute (R25CA057712, R01CA112223, K07CA140159)
- Topics
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Health Sciences › Medicine › Oncology › Cancer survivorship and care
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- adjuvant endocrine therapy, breast cancer survivors, medication adherence, treatment persistence, tamoxifen, aromatase inhibitors, hormone receptor-positive breast cancer, out-of-pocket costs, treatment side effects, behavioral interventions
- MeSH terms
- Breast Neoplasms, Clinical Trials as Topic, Female, Humans, Neoplasms, Hormone-Dependent, Chemotherapy, Adjuvant, Survivors, Antineoplastic Agents, Hormonal, Medication Adherence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
